Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/45216
Title: Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months
Authors: Wu, Lihteh
Arevalo, Jose Fernando
Berrocal, Maria Hortensia
Maia, Mauricio [UNIFESP]
Roca, Jose Antonio
Morales-Canton, Virgilio
Alezzandrini, Arturo A.
Diaz-Llopis, Manuel Jose
Inst Cirugia Ocular
Ctr Caracas
Univ Puerto Rico
Universidade Federal de São Paulo (UNIFESP)
Clin Ricardo Palma
Hosp Luis Sanchez Bulnes
Univ Buenos Aires
Inst Oftalmol Valencia
Keywords: bevacizumab
branch retinal vein occlusion
intravitreal injections
macular edema
retinal vein occlusions
VEGF
Issue Date: 1-Nov-2009
Publisher: Lippincott Williams & Wilkins
Citation: Retina-the Journal Of Retinal And Vitreous Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 29, n. 10, p. 1396-1403, 2009.
Abstract: Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity (BCVA) after injecting 1.25 mg or 2.5 mg of bevacizumab as needed in patients with primary macular edema secondary to branch retinal vein occlusion.Methods: An interventional, retrospective, comparative multicenter study was conducted of 63 eyes with macular edema secondary to branch retinal vein occlusion that were treated primarily with intravitreal bevacizumab (38 eyes, 1.25 mg; 25 eyes, 2.5 mg). The main outcome measures were the CMT and the change of BCVA at 24 months.Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye was 3.6 in the 1.25-mg group and 4.3 in the 2.5-mg group (P = 0.4770). At 24 months, in the 1.25-mg group, the logarithm of the minimum angle of resolution BCVA improved from baseline 0.38 +/- 0.63 (P < 0.0001) units to 0.64 +/- 0.6 units for the 2.5-mg group (P < 0.0001). In the 1.25-mg group, 26 (68%) eyes gained >= 3 of Early Treatment of Diabetic Retinopathy Study visual acuity and 2 (5%) eyes lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg group, 18 (72%) eyes improved >= 3 of Early Treatment of Diabetic Retinopathy Study visual acuity, and none of the eyes lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg group improved from 453 +/- 140 mu m to 244 +/- 125 mu m (P < 0.0001) versus 444 +/- 175 mu m to 234 +/- 80 mu m in the 2.5-mg group (P < 0.0001). There were no cases of endophthalmitis. No systemic adverse events were reported.Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving BCVA and reducing CMT in macular edema secondary to branch retinal vein occlusion. No statistically significant differences were found between the two dose groups with regard to the number of injections, CMT, and change in BCVA. RETINA 29:1396-1403, 2009
URI: http://repositorio.unifesp.br/11600/45216
ISSN: 0275-004X
Other Identifiers: http://dx.doi.org/10.1097/IAE.0b013e3181bcef53
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.